Literature DB >> 6210706

Metabolic clearance and plasma half-disappearance time of D-TRP6 and exogenous luteinizing hormone-releasing hormone.

J L Barron, R P Millar, D Searle.   

Abstract

The MCR and t1/2 of D-Trp6 LRH, a potent analog of LRH, were compared to those of exogenous LRH. Studies were performed on eight normal subjects during and after cessation of a constant infusion of D-Trp6 LRH and LRH. The D-Trp6 LRH and LRH were quantitated individually by sensitive and specific RIAs which did not cross-react with the other peptide infused or fragments of the degraded peptides. High performance liquid chromatography of plasma from a patient infused with D-Trp6 LRH alone yielded one peak, which coeluted with D-Trp6 LRH. The kinetics of peptide clearance were biphasic, with a rapid and a slow component of elimination. The t1/2 of the rapid component of D-Trp6 LRH clearance was 18.7 +/- 1.8 (SEM) min. This was significantly longer (P less than 0.001) than the t1/2 for the LRH of 7.8 +/- 1.1 min. The MCRs for D-Trp6 LRH and LRH were 503.4 +/- 196.4 and 1766.6 +/- 404.3 ml/min, respectively (P less than 0.01). The longer t1/2 of D-Trp6 LRH compared to that of LRH reflects the slower clearance, which is probably due to a decreased rate of degradation. These findings indicated that the enhanced bioactivity of D-Trp6 LRH is in part due to a decreased rate of degradation.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6210706     DOI: 10.1210/jcem-54-6-1169

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

Review 1.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

2.  Radioimmunoassay for 6-D-tryptophan analog of luteinizing hormone-releasing hormone: measurement of serum levels after administration of long-acting microcapsule formulations.

Authors:  M Mason-Garcia; S Vigh; A M Comaru-Schally; T W Redding; A Somogyvari-Vigh; J Horvath; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

Review 3.  Clinical pharmacokinetics of goserelin.

Authors:  I D Cockshott
Journal:  Clin Pharmacokinet       Date:  2000-07       Impact factor: 6.447

4.  Population pharmacokinetic/pharmacodynamic (PK/PD) modelling of the hypothalamic-pituitary-gonadal axis following treatment with GnRH analogues.

Authors:  Christoffer W Tornøe; Henrik Agersø; Thomas Senderovitz; Henrik A Nielsen; Henrik Madsen; Mats O Karlsson; E Niclas Jonsson
Journal:  Br J Clin Pharmacol       Date:  2006-11-10       Impact factor: 4.335

5.  Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase III study.

Authors:  Eija A Lundström; Rupert K Rencken; Johann H van Wyk; Lance J E Coetzee; Johann C M Bahlmann; Simon Reif; Erdam A Strasheim; Martin C Bigalke; Alan R Pontin; Louis Goedhals; Douw G Steyn; Chris F Heyns; Luigi A Aldera; Thomas M Mackenzie; Daniela Purcea; Pierre Y Grosgurin; Hervé C Porchet
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

Review 6.  Male hypogonadism.

Authors:  Andrea M Isidori; Elisa Giannetta; Andrea Lenzi
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

7.  Effect of dextran on the release of gonadotropin-releasing hormone (GnRH) injected into rats: plasma GnRH and gonadotropin response.

Authors:  N Heinrich; D Lorenz; H Berger; K Fechner; H E Schmidt; H Schäfer; B Mehlis
Journal:  Pharm Res       Date:  1985-09       Impact factor: 4.200

8.  Six-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfort.

Authors:  E David Crawford; Jason M Phillips
Journal:  Cancer Manag Res       Date:  2011-07-20       Impact factor: 3.989

Review 9.  Triptorelin embonate (6-month formulation).

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2010-02-12       Impact factor: 11.431

10.  Probing the GnRH receptor agonist binding site identifies methylated triptorelin as a new anti-proliferative agent.

Authors:  Kevin Morgan; Samuel P Leighton; Robert P Millar
Journal:  J Mol Biochem       Date:  2012-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.